RxDoctor Payments Data

Ibraheem Yousef, MD

Critical Care Medicine · Munster, INNPI 1861756488

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (46.9%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 74.6% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2024 at $2,614 and has fallen 93.5% since, to $170 in 2025.

$3,202in general payments, 2019–2025

Across 22 payments — averaging $145.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$2K
  • Medical Device Business Services, Inc.$247
  • Pulmonx Corporation$241
  • Johnson & Johnson$210
  • AstraZeneca$95
  • Ceribell, Inc.$19

What the payments were for

  • Travel & lodging$1,03432%
  • Food & beverage$66821%
  • Education$1,50047%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,202 in reported general payments places this provider in the 80th percentile of 158 critical care medicine providers in Indiana.

See all critical care medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$269,353
Medicare patients
674
Services billed
2,333

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate24$302,576
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$48,381
Spiriva RespimatTiotropium Bromide64$38,686
Breztri AerosphereBudesonide/Glycopyr/Formoterol44$27,493
Stiolto RespimatTiotropium Br/Olodaterol Hcl49$25,604
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$13,735
Bevespi AerosphereGlycopyrrolate/Formoterol Fum20$12,210
EliquisApixaban11$6,200
Incruse ElliptaUmeclidinium Bromide11$4,089
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate28$3,687
Albuterol Sulfate HfaAlbuterol Sulfate86$1,996
Mycophenolate Mofetil12$1,209
Varenicline Tartrate11$1,137
Montelukast Sodium25$1,010
Fluticasone Propionate33$506

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere, Bevespi Aerosphere$95$39,70364 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 158 critical care medicine providers in Indiana.

Other critical care medicine in Munster

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →